Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis.
Heterogeneous resistance to vancomycin is thought to precede emergence of intermediate susceptibility to vancomycin in Staphylococcus aureus, but the clinical significance of heterogeneous resistance is unknown. Paired S. aureus isolates from a patient with endocarditis who relapsed after vancomycin treatment were tested for heterogeneous resistance to vancomycin. The pretreatment and the relapse clinical isolates (strains SF1 and SF2, respectively) were genotyped by pulsed-field gel electrophoresis. Susceptibility to vancomycin was assessed by the broth dilution method, population analysis, and time-kill studies and in the rabbit model of endocarditis. Strains SF1 and SF2 had similar genotypes, and the vancomycin MICs for the strains were </=2 micro g/ml. SF2 exhibited heterogeneous resistance to vancomycin. Vancomycin eradicated SF1 in the rabbit model of endocarditis, while SF2 persisted at pretreatment levels. Vancomycin treatment failure in this patient with endocarditis was attributable to heterogeneous resistance to vancomycin.
Moore
Matthew R
MR
Division of Infectious Diseases, San Francisco General Hospital, California, USA. mmoore4@cdc.gov
Perdreau-Remington
Françoise
F
Chambers
Henry F
HF
D000818:Animals; D004195:Disease Models, Animal; D024881:Drug Resistance, Bacterial; D004697:Endocarditis, Bacterial / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011817:Rabbits; D013203:Staphylococcal Infections / Q000188:drug therapy*; D017211:Treatment Failure; D014640:Vancomycin / Q000627:therapeutic use*
D014640:Vancomycin